Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Wilding

Showing results (61-70 of 73) with videos related to

Pageof 8
Sort By:
Diabetes & Metabolic Syndrome|March 23, 2017
Consensus recommendations on exploring effective solutions for the rising cost of diabetesShaukat M Sadikot, Ashok Kumar Das, John Wilding, et al.
Obesity (Silver Spring, Md.)|February 14, 2025
Safety profile of semaglutide versus placebo in the SELECT study: a randomized controlled trialRobert F Kushner, Donna H Ryan, John Deanfield, et al.
Current Medical Research and Opinion|December 24, 2019
Real-world outcomes of treatment with insulin glargine 300 U/mL versus standard-of-care in people with uncontrolled type 2 diabetes mellitusNick Freemantle, Didac Mauricio, Andrea Giaccari, et al.
European Journal of Heart Failure|December 3, 2020
Relationship between baseline cardiac biomarkers and cardiovascular death or hospitalization for heart failure with and without sodium-glucose co-transporter 2 inhibitor therapy in DECLARE-TIMI 58Thomas A Zelniker, David A Morrow, Ofri Mosenzon, et al.
JAMA Cardiology|March 1, 2023
Association of Cardiac Biomarkers With Major Adverse Cardiovascular Events in High-risk Patients With Diabetes: A Secondary Analysis of the DECLARE-TIMI 58 TrialThomas A Zelniker, Stephen D Wiviott, Ofri Mosenzon, et al.
Pilot and Feasibility Studies|September 10, 2022
A group-based behavioural intervention for weight management (PROGROUP) versus usual care in adults with severe obesity: a feasibility randomised controlled trial protocolDawn Swancutt, Mark Tarrant, Wendy Ingram, et al.
Obesity (Silver Spring, Md.)|November 3, 2023
Diazoxide choline extended-release tablet in people with Prader-Willi syndrome: results from long-term open-label studyJennifer L Miller, Evelien Gevers, Nicola Bridges, et al.
BMJ Open|June 17, 2021
Realising the full potential of data-enabled trials in the UK: a call for actionMatthew R Sydes, Yolanda Barbachano, Louise Bowman, et al.
Hormones (Athens, Greece)|August 6, 2025
EndoBridge 2024: pearls and highlightsBulent Okan Yildiz, Eleni Armeni, Chrysanthi Balodimou, et al.
Cardiovascular Diabetology|March 17, 2023
CVOT Summit 2022 Report: new cardiovascular, kidney, and glycemic outcomesOliver Schnell, Tadej Battelino, Richard Bergenstal, et al.
Pageof 8

Showing results (61-70 of 73) with videos related to

Sort By:
Pageof 8
Diabetes & Metabolic Syndrome|March 23, 2017
Consensus recommendations on exploring effective solutions for the rising cost of diabetesShaukat M Sadikot, Ashok Kumar Das, John Wilding, et al.
Obesity (Silver Spring, Md.)|February 14, 2025
Safety profile of semaglutide versus placebo in the SELECT study: a randomized controlled trialRobert F Kushner, Donna H Ryan, John Deanfield, et al.
Current Medical Research and Opinion|December 24, 2019
Real-world outcomes of treatment with insulin glargine 300 U/mL versus standard-of-care in people with uncontrolled type 2 diabetes mellitusNick Freemantle, Didac Mauricio, Andrea Giaccari, et al.
European Journal of Heart Failure|December 3, 2020
Relationship between baseline cardiac biomarkers and cardiovascular death or hospitalization for heart failure with and without sodium-glucose co-transporter 2 inhibitor therapy in DECLARE-TIMI 58Thomas A Zelniker, David A Morrow, Ofri Mosenzon, et al.
JAMA Cardiology|March 1, 2023
Association of Cardiac Biomarkers With Major Adverse Cardiovascular Events in High-risk Patients With Diabetes: A Secondary Analysis of the DECLARE-TIMI 58 TrialThomas A Zelniker, Stephen D Wiviott, Ofri Mosenzon, et al.
Pilot and Feasibility Studies|September 10, 2022
A group-based behavioural intervention for weight management (PROGROUP) versus usual care in adults with severe obesity: a feasibility randomised controlled trial protocolDawn Swancutt, Mark Tarrant, Wendy Ingram, et al.
Obesity (Silver Spring, Md.)|November 3, 2023
Diazoxide choline extended-release tablet in people with Prader-Willi syndrome: results from long-term open-label studyJennifer L Miller, Evelien Gevers, Nicola Bridges, et al.
BMJ Open|June 17, 2021
Realising the full potential of data-enabled trials in the UK: a call for actionMatthew R Sydes, Yolanda Barbachano, Louise Bowman, et al.
Hormones (Athens, Greece)|August 6, 2025
EndoBridge 2024: pearls and highlightsBulent Okan Yildiz, Eleni Armeni, Chrysanthi Balodimou, et al.
Cardiovascular Diabetology|March 17, 2023
CVOT Summit 2022 Report: new cardiovascular, kidney, and glycemic outcomesOliver Schnell, Tadej Battelino, Richard Bergenstal, et al.
Pageof 8